Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trialEsther Natalie Olíva, Roberto Latagliata, Flavia Salvi et al.|The Lancet Haematology|2017Cited by 163
Early lenalidomide treatment for low and intermediate‐1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependenceEsther Natalie Olíva, Roberto Latagliata, Michael Lauseker et al.|Cancer Medicine|2015Cited by 23
Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, TrialEsther Natalie Olíva, Roberto Latagliata, Valeria Santini et al.|Blood|2015Cited by 13